BACKGROUND:Kidney transplant recipients (KTRs) have increased risk of cardiovascular disease (CVD). Our objective is to describe the prevalence of CVD risk factors applying standard criteria and use of CVD risk factor-lowering medications in contemporary KTRs. METHODS: The Folic Acid for Vascular Outcome Reduction in Transplantation study enrolled and collected medication data on 4107 KTRs with elevated homocysteine and stable graft function an average of five yr post-transplant. RESULTS:CVD risk factors were common (hypertension or use of blood pressure (BP) lowering medication in 92%, borderline or elevated low-density lipoprotein (LDL) or use of lipid-lowering agent in 66%, history of diabetes mellitus in 41%, and obesity in 38%); prevalent CVD was reported in 20% of study participants. National Kidney Foundation BP guidelines (BP <130/80 mmHg) were not met by 69% of participants. Uncontrolled hypertension (BP of 140/90 mmHg or higher) was present in 44% of those taking antihypertension medication; 18% of participants had borderline or elevated LDL, of which 60% were untreated, and 31% of the participants with prevalent CVD were not using an antiplatelet agent. CONCLUSION: There is opportunity to improve treatment and control of traditional CVD risk factors in kidney transplant recipients.
RCT Entities:
BACKGROUND: Kidney transplant recipients (KTRs) have increased risk of cardiovascular disease (CVD). Our objective is to describe the prevalence of CVD risk factors applying standard criteria and use of CVD risk factor-lowering medications in contemporary KTRs. METHODS: The Folic Acid for Vascular Outcome Reduction in Transplantation study enrolled and collected medication data on 4107 KTRs with elevated homocysteine and stable graft function an average of five yr post-transplant. RESULTS: CVD risk factors were common (hypertension or use of blood pressure (BP) lowering medication in 92%, borderline or elevated low-density lipoprotein (LDL) or use of lipid-lowering agent in 66%, history of diabetes mellitus in 41%, and obesity in 38%); prevalent CVD was reported in 20% of study participants. National Kidney Foundation BP guidelines (BP <130/80 mmHg) were not met by 69% of participants. Uncontrolled hypertension (BP of 140/90 mmHg or higher) was present in 44% of those taking antihypertension medication; 18% of participants had borderline or elevated LDL, of which 60% were untreated, and 31% of the participants with prevalent CVD were not using an antiplatelet agent. CONCLUSION: There is opportunity to improve treatment and control of traditional CVD risk factors in kidney transplant recipients.
Authors: W P D Lemahieu; M Hermann; A Asberg; K Verbeke; H Holdaas; Y Vanrenterghem; B D Maes Journal: Am J Transplant Date: 2005-09 Impact factor: 8.086
Authors: Andrew G Bostom; Myra A Carpenter; John W Kusek; Lawrence G Hunsicker; Marc A Pfeffer; Andrew S Levey; Paul F Jacques; Joyce McKenney Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Luís Henrique W Gowdak; Flávio J de Paula; Luiz Antonio M César; Eulógio E Martinez Filho; Luiz Estevan Ianhez; Eduardo Moacyr Krieger; José Antonio F Ramires; José Jayme G de Lima Journal: Coron Artery Dis Date: 2007-11 Impact factor: 1.439
Authors: Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Alan Reed; Bruce Kaplan Journal: Am J Transplant Date: 2004-10 Impact factor: 8.086
Authors: Andrew G Bostom; Myra A Carpenter; Lawrence Hunsicker; Paul F Jacques; John W Kusek; Andrew S Levey; Joyce L McKenney; Renee Y Mercier; Marc A Pfeffer; Jacob Selhub Journal: Am J Kidney Dis Date: 2008-11-20 Impact factor: 8.860
Authors: David J Taber; Kelly J Hunt; Cory E Fominaya; Elizabeth H Payne; Mulugeta Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede Journal: Hypertension Date: 2016-07-11 Impact factor: 10.190
Authors: Amanda J Vinson; Sunita Singh; Steven Chadban; David Cherney; Osama Gaber; John S Gill; Erika Helgeson; Charles A Herzog; Meg Jardine; Vivekanand Jha; Bertram L Kasiske; Roslyn B Mannon; Erin D Michos; Amy K Mottl; Kristin Newby; Prabir Roy-Chaudhury; Deirdre Sawinski; Adnan Sharif; Vikas S Sridhar; Katherine R Tuttle; David M Vock; Arthur Matas Journal: J Am Soc Nephrol Date: 2022-03-15 Impact factor: 14.978
Authors: David J Taber; Kevin Douglass; Titte Srinivas; John W McGillicuddy; Charles F Bratton; Kenneth D Chavin; Prabhakar K Baliga; Leonard E Egede Journal: Am J Nephrol Date: 2014-06-25 Impact factor: 3.754
Authors: Myra A Carpenter; Alin John; Matthew R Weir; Stephen R Smith; Lawrence Hunsicker; Bertram L Kasiske; John W Kusek; Andrew Bostom; Anastasia Ivanova; Andrew S Levey; Scott Solomon; Todd Pesavento; Daniel E Weiner Journal: J Am Soc Nephrol Date: 2014-03-13 Impact factor: 10.121